452
Participants
Start Date
May 31, 1993
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
cyclophosphamide
cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
doxorubicin hydrochloride
doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
epirubicin hydrochloride
epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
tamoxifen citrate
Tamoxifen 20 mg daily.
toremifene
Toremifene 60 mg daily.
Auckland Adventist Hospital, Auckland
Hopital des Cadolles, Neuchatel, Neuchâtel
Royal Prince Alfred Hospital, Sydney, Sydney
Anti-Cancer Council of Victoria, Melbourne, Carlton South
Royal Adelaide Hospital, Adelaide
Sir Charles Gairdner Hospital, Perth, Perth
Groote Schuur Hospital, Cape Town, Cape Town
Istituto Europeo Di Oncologia, Milan
Universita di Brescia, Brescia
Centro di Riferimento Oncologico - Aviano, Aviano
Ospedale Civile Rimini, Rimini
Newcastle Mater Misericordiae Hospital, Newcastle
Ospedale San Eugenio, Rome
Institute of Oncology, Ljubljana, Ljubljana
Sahlgrenska University Hospital, Gothenburg (Goteborg)
University Hospital, Basel
Inselspital, Bern, Bern
Centre Hospitalier Universitaire Vaudois, Lausanne
Kantonsspital - Saint Gallen, Sankt Gallen
Universitaetsspital, Zurich
ETOP IBCSG Partners Foundation
NETWORK